Valeritas touts new data for insulin delivery device

Valeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes.

In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas touts new data for insulin delivery device appeared first on MassDevice.

from MassDevice https://ift.tt/2rRgxLv